Literature DB >> 11173885

Cerebrospinal fluid tau levels increase with age in healthy individuals.

M Blomberg1, M Jensen, H Basun, L Lannfelt, L O Wahlund.   

Abstract

Cerebrospinal fluid (CSF) tau is a promising biochemical ante-mortem marker for Alzheimer's disease (AD). Levels are increased in AD compared to other dementias, neurological diseases and healthy controls. An age-related decrease in both soluble tau and tau bound to paired helical filaments has been shown in brains from non-demented subjects. To study tau levels in normal ageing, we investigated CSF in 29 healthy individuals aged 45-80 years. A statistically significant increase in CSF tau with increasing age was found which might be caused by neuronal loss during normal ageing and redistribution of soluble tau from the brain into CSF. We could not demonstrate any influence by the APOE genotype, though larger populations have to be investigated to confirm this result. In conclusion, we found an age-dependent increase in CSF tau in healthy individuals. We emphasise the importance of establishing an age-dependent interval of CSF tau in non-demented subjects. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11173885     DOI: 10.1159/000051246

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  11 in total

1.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

2.  Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.

Authors:  Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

Review 3.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

4.  CSF phospho-tau is independent of age, cognitive status and gender of neurological patients.

Authors:  Armin Scheurich; Peter P Urban; Nassrin Koch-Khoury; Andreas Fellgiebel
Journal:  J Neurol       Date:  2009-11-17       Impact factor: 4.849

5.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Authors:  Lidia Glodzik-Sobanska; Elizabeth Pirraglia; Miroslaw Brys; Susan de Santi; Lisa Mosconi; Kenneth E Rich; Remigiusz Switalski; Leslie Saint Louis; Martin J Sadowski; Frank Martiniuk; Pankaj Mehta; Domenico Pratico; Raymond P Zinkowski; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-10-24       Impact factor: 4.673

6.  Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease.

Authors:  Elias Granadillo; Pongsatorn Paholpak; Mario F Mendez; Edmond Teng
Journal:  Dement Geriatr Cogn Disord       Date:  2017-07-05       Impact factor: 2.959

Review 7.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

8.  Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.

Authors:  Jacek Jaworski; Marek Psujek; Marzena Janczarek; Małgorzata Szczerbo-Trojanowska; Halina Bartosik-Psujek
Journal:  Ups J Med Sci       Date:  2012-05-04       Impact factor: 2.384

Review 9.  A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.

Authors:  Emma Lawrence; Carolin Vegvari; Alison Ower; Christoforos Hadjichrysanthou; Frank De Wolf; Roy M Anderson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42.

Authors:  Camilla Lauridsen; Sigrid B Sando; Ina Møller; Guro Berge; Precious K Pomary; Gøril R Grøntvedt; Øyvind Salvesen; Geir Bråthen; Linda R White
Journal:  Front Aging Neurosci       Date:  2017-06-28       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.